Skip to content

Remission of Severe Opioid Use Disorder with Ibogaine: A Case Report.

Laurie Cloutier-Gill, Evan Wood, Trevor Millar, Caroline Ferris, M Eugenia Socias

Journal of Psychoactive Drugs 2016 DOI: 10.1080/02791072.2016.1180467 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Case study Case report Peer reviewed
Sample size 1
Population 37-year-old female with severe opioid use disorder
Intervention Ibogaine
Duration Four-day treatment, 18-month follow-up
Topics Ibogaine Addiction
Keywords Methadone maintance therapy Opioid agonist treatment Opioid use disorders Ibogaine treatment Remission Abstinence Long-term recovery Treatment-resistant opioid addiction Standard opioid therapies Methadone maintenance therapy Standard care
Citations 22
Key findings A four-day ibogaine treatment was associated with an ongoing 18-month period of abstinence in a patient with treatment-refractory severe opioid use disorder.

Abstract

Opioid use disorders (OUD) translate into major health, social, and economic consequences. Opioid agonist medications, which generally require long-term administration, are the mainstay pharmacological treatment of OUD. However, a large proportion of individuals with OUD either refuse or fail to respond to these therapies. Ibogaine, a naturally occurring substance found in the Tabernanthe iboga plant, has shown potential to bring about transformative or spiritual experiences that have reportedly been associated with long-term abstinece. Although research on ibogaine is limited, an ibogaine subculture persists, offering unregulated ibogaine preparations for the treatment of addiction. We describe the case of a 37-year-old female with a 19-year history of severe OUD achieving an ongoing 18-month period of abstinence following a four-day ibogaine treatment. Her previous longest period of continuous abstinence from opioids was two months while on methadone. No safety issues associated with ibogaine were observed. A four-day treatment with ibogaine was succesful in achieving long-term remission of a previously treatment-refractory patient with severe OUD. While rigorous trials are required to establish safety and efficacy, future studies should seek to delineate the potential role of ibogaine or other molecules that may produce transformative experiences for individuals with substance use disorder.

Comparable studies

Other case reports and case series on ibogaine for addiction, most cited first.

Study Year Design Participants
Long-QT Syndrome Induced by the Antiaddiction Drug Ibogaine A 31-year-old woman 2009 Case study n = 1
A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder. 31-year-old male military veteran with moderate alcohol use disorder 2018 Case study n = 1
Ibogaine Consumption With Seizure-Like Episodes, QTc-Prolongation, and Captured Cardiac Dysrhythmias. 34-year-old white woman with heroin and cocaine use disorder 2019 Case study n = 1
Novel treatment of opioid use disorder using ibogaine and iboga in two adults Individuals with opioid use disorder accessing ibogaine through private unregulated... 2020 Case series n = 2
Risk management in a global market of alternative addiction care: a case study of the ibogaine medical subculture 2025 Case study

Citations in the library

Explore topics

By condition and practice